GlassScriptPhysician profile
Omer Abdul Hamid
NPI 1780048397
$282,505.58
in general payments reported to CMS, 2019-2025
23 companies · $71K in 2025
The $71K reported for 2025 was more than what 98% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90K · 2022: $556 · 2023: $46K · 2024: $75K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $82K · Consulting Fee: $70K · Travel and Lodging: $19K · Food and Beverage: $11K · Honoraria: $9,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $82,331.00 |
| Consulting Fee | $70,027.00 |
| Travel and Lodging | $19,164.59 |
| Food and Beverage | $10,643.80 |
| Honoraria | $9,752.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $124,911.51 | 2021-2025 | Skyclarys, Spinraza, Zurzuvae |
| Genentech USA, INC. | $73,111.51 | 2022-2025 | Evrysdi |
| Sarepta Therapeutics, INC. | $52,938.63 | 2023-2025 | Elevidys |
| Catalyst Pharmaceuticals, INC. | $11,267.66 | 2023-2025 | Firdapse |
| Itf Therapeutics LLC | $6,138.23 | 2024-2025 | |
| Ptc Therapeutics, INC. | $4,808.08 | 2023-2025 | |
| Pfizer INC. | $3,822.99 | 2023-2024 | |
| Ucb, INC. | $2,042.82 | 2023-2025 | Fintepla, Briviact |
| Genentech, INC. | $1,021.66 | 2022-2025 | Evrysdi |
| Livanova USA, INC. | $760.63 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $359.66 | 2023-2025 | Daybue |
| Ns Pharma, INC. | $325.64 | 2023-2024 | Viltepso |
| Immedica Pharma US, INC. | $255.46 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $244.95 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $130.30 | 2025 | Ultomiris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $116.01 | 2022-2023 | Zolgensma |
| Jazz Pharmaceuticals INC. | $73.36 | 2023-2025 | Epidiolex |
| Biocodex, INC. | $61.98 | 2023-2025 | Diacomit |
| Intrabio INC | $34.41 | 2025 | Aqneursa |
| Eisai INC. | $30.42 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.03 | 2023 | Zonisade, Eprontia, Fleqsuvy |
| Neurelis, INC. | $16.82 | 2023 | Valtoco |
| Biomarin Pharmaceutical INC. | $15.82 | 2025 | Brineura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omer Abdul Hamid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.